>
Switch to:

Cellectar Biosciences ROE %

: -56.38% (As of Sep. 2021)
View and export this data going back to 2005. Start your Free Trial

ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. Cellectar Biosciences's annualized net income attributable to common stockholders for the quarter that ended in Sep. 2021 was $-23.28 Mil. Cellectar Biosciences's average Total Stockholders Equity over the quarter that ended in Sep. 2021 was $41.28 Mil. Therefore, Cellectar Biosciences's annualized ROE % for the quarter that ended in Sep. 2021 was -56.38%.

The historical rank and industry rank for Cellectar Biosciences's ROE % or its related term are showing as below:

NAS:CLRB' s ROE % Range Over the Past 10 Years
Min: -191.76   Med: -127.61   Max: -47.28
Current: -53.65

-191.76
-47.28

During the past 13 years, Cellectar Biosciences's highest ROE % was -47.28%. The lowest was -191.76%. And the median was -127.61%.

NAS:CLRB's ROE % is ranked lower than
99.99% of the 275 Companies
in the Biotechnology industry.

( Industry Median: -68.79 vs. NAS:CLRB: -53.65 )

Cellectar Biosciences ROE % Historical Data

The historical data trend for Cellectar Biosciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -123.24 -123.58 -128.93 -126.28 -47.28

Cellectar Biosciences Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -86.39 -40.72 -48.63 -51.43 -56.38

Competitive Comparison

For the Biotechnology subindustry, Cellectar Biosciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Cellectar Biosciences ROE % Distribution

For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's ROE % distribution charts can be found below:

* The bar in red indicates where Cellectar Biosciences's ROE % falls into.



Cellectar Biosciences ROE % Calculation

Cellectar Biosciences's annualized ROE % for the fiscal year that ended in Dec. 2020 is calculated as

ROE %=Net Income attributable to Common Stockholders (A: Dec. 2020 )/( (Total Stockholders Equity (A: Dec. 2019 )+Total Stockholders Equity (A: Dec. 2020 ))/ count )
=-15.094/( (9.059+54.795)/ 2 )
=-15.094/31.927
=-47.28 %

Cellectar Biosciences's annualized ROE % for the quarter that ended in Sep. 2021 is calculated as

ROE %=Net Income attributable to Common Stockholders (Q: Sep. 2021 )/( (Total Stockholders Equity (Q: Jun. 2021 )+Total Stockholders Equity (Q: Sep. 2021 ))/ count )
=-23.276/( (43.983+38.585)/ 2 )
=-23.276/41.284
=-56.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Sep. 2021) net income attributable to common stockholders data. ROE % is displayed in the 30-year financial page.


Cellectar Biosciences  (NAS:CLRB) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %**(Q: Sep. 2021 )
=Net Income/Total Stockholders Equity
=-23.276/41.284
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-23.276 / 0)*(0 / 44.8455)*(44.8455 / 41.284)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.0863
=ROA %*Equity Multiplier
=N/A %*1.0863
=-56.38 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %**(Q: Sep. 2021 )
=Net Income/Total Stockholders Equity
=-23.276/41.284
=(Net Income /Pre-Tax Income) * (Pre-Tax Income/Operating Income) * (Operating Income/Revenue) * (Revenue/Total Assets) * (Total Assets/Total Stockholders Equity)
= (-23.276 / -23.276) * (-23.276 / -23.28) * (-23.28 / 0) * (0 / 44.8455) * (44.8455 / 41.284)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9998 * N/A % * 0 * 1.0863
=-56.38 %

Note: The net income attributable to common stockholders data used here is four times the quarterly (Sep. 2021) net income attributable to common stockholders data. The Revenue data used here is four times the quarterly (Sep. 2021) revenue data. The same rule applies to Pre-Tax Income and Operating Income.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Cellectar Biosciences ROE % Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectar Biosciences Business Description

Cellectar Biosciences logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical stage biopharmaceutical company. It focusses on development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company's pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic phospholipid drug conjugates. Its portfolio of products in development includes CLR 131, CTX Product Portfolio consisting of CTX CLR 1800-P, CTX CLR 1602-PTX and CTX CLR 1700, CLR 125, CLR 124, and CLR 1502.
Executives
Friend John E. Ii officer: VP, Chief Medical Officer 26 ORCHARD LANE COLT NECK NJ 07722
Swirsky Douglas J director C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD SUITE 455 ROCKVILLE MD 20850
Neis John director 505 S. ROSA ROAD, SUITE 201 MADISON WI 53719
Hill Stephen A director 50 AVENUE GENERAL DE GAULLE BRUXELLES C9 9999999999
Driscoll Frederick W director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: DRISCOLL FREDERICK W a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Loren Stefan director 3226 AVENIDA DE SUENO CARLSBAD CA 92009
Elefant Dov officer: Chief Financial Officer EPICEPT CORPORATION 270 SYLVAN AVENUE ENGLEWOOD CLIFFS NJ 07632
Caruso James V director, officer: President and CEO C/O CELLECTAR BIOSCIENCES, INC. 8383 GREENWAY BLVD STE 600 MIDDLETON WI 53562
Longcor Jarrod officer: Chief Business Officer C/O RIB-X PHARMACEUTICALS, INC. 300 GEORGE STREET, SUITE 301 NEW HAVEN CT 06511
Grachev Igor D officer: Chief Medical Officer 15 REID LANE MILLSTONE TWP NJ 08535
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD MALVERN PA 19355
Posner Brian M officer: Chief Financial Officer 1590 REED ROAD PENNINGTON NJ 08534
Hamill John P. officer: Interim CFO 4092 NEW HOPE ROAD FURLONG PA 18925
Kolean Chad J officer: VP, Chief Financial Officer C/O CELLECTAR BIOSCIENCES, INC. 3301 AGRICULTURE DRIVE MADISON WI 53716
Hertzberg Richard other: significant owner 1329 STRATFORD COURT DEL MAR CA 92014

Cellectar Biosciences Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)